Cargando…
Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis
Recombinant-modified vaccinia virus Ankara (rMVA) is known to elicit potent antitumor immune responses in preclinical models due to its inherent ability to activate the innate immune system and the activation of adaptive responses mediated by the expression of tumor antigens and costimulus-providing...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291657/ https://www.ncbi.nlm.nih.gov/pubmed/35859732 http://dx.doi.org/10.1080/2162402X.2022.2098657 |
_version_ | 1784749185496514560 |
---|---|
author | Bella, Ángela Arrizabalaga, Leire Di Trani, Claudia Augusta Cirella, Assunta Fernandez-Sendin, Myriam Gomar, Celia Russo-Cabrera, Joan Salvador Rodríguez, Inmaculada González-Gomariz, José Alvarez, Maite Teijeira, Álvaro Medina-Echeverz, José Hinterberger, Maria Hochrein, Hubertus Melero, Ignacio Berraondo, Pedro Aranda, Fernando |
author_facet | Bella, Ángela Arrizabalaga, Leire Di Trani, Claudia Augusta Cirella, Assunta Fernandez-Sendin, Myriam Gomar, Celia Russo-Cabrera, Joan Salvador Rodríguez, Inmaculada González-Gomariz, José Alvarez, Maite Teijeira, Álvaro Medina-Echeverz, José Hinterberger, Maria Hochrein, Hubertus Melero, Ignacio Berraondo, Pedro Aranda, Fernando |
author_sort | Bella, Ángela |
collection | PubMed |
description | Recombinant-modified vaccinia virus Ankara (rMVA) is known to elicit potent antitumor immune responses in preclinical models due to its inherent ability to activate the innate immune system and the activation of adaptive responses mediated by the expression of tumor antigens and costimulus-providing molecules, such as CD40L and CD137L. Here, we evaluated different rMVA vectors in preclinical peritoneal carcinomatosis models (ID8.OVA-Vegf/GFP and MC38). We compared rMVA vectors expressing a tumor antigen (OVA or gp70) either alone or co-expressed with CD40L or/and CD137L. In tumor-free mice, the vector coding for the triple combination was only slightly superior, whereas, in tumor-bearing animals, we observed a synergistic induction of T lymphocytes specific against vector-encoded and non-encoded tumor-associated antigens. The enhanced activation of the immune response was associated with improved survival in mice with peritoneal carcinomatosis treated with a rMVA vector encoding both CD40L and CD137L. Thus, the triple transgene combination in vaccinia viral vectors represents a promising strategy for the treatment of peritoneal carcinomatosis. |
format | Online Article Text |
id | pubmed-9291657 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-92916572022-07-19 Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis Bella, Ángela Arrizabalaga, Leire Di Trani, Claudia Augusta Cirella, Assunta Fernandez-Sendin, Myriam Gomar, Celia Russo-Cabrera, Joan Salvador Rodríguez, Inmaculada González-Gomariz, José Alvarez, Maite Teijeira, Álvaro Medina-Echeverz, José Hinterberger, Maria Hochrein, Hubertus Melero, Ignacio Berraondo, Pedro Aranda, Fernando Oncoimmunology Brief Report Recombinant-modified vaccinia virus Ankara (rMVA) is known to elicit potent antitumor immune responses in preclinical models due to its inherent ability to activate the innate immune system and the activation of adaptive responses mediated by the expression of tumor antigens and costimulus-providing molecules, such as CD40L and CD137L. Here, we evaluated different rMVA vectors in preclinical peritoneal carcinomatosis models (ID8.OVA-Vegf/GFP and MC38). We compared rMVA vectors expressing a tumor antigen (OVA or gp70) either alone or co-expressed with CD40L or/and CD137L. In tumor-free mice, the vector coding for the triple combination was only slightly superior, whereas, in tumor-bearing animals, we observed a synergistic induction of T lymphocytes specific against vector-encoded and non-encoded tumor-associated antigens. The enhanced activation of the immune response was associated with improved survival in mice with peritoneal carcinomatosis treated with a rMVA vector encoding both CD40L and CD137L. Thus, the triple transgene combination in vaccinia viral vectors represents a promising strategy for the treatment of peritoneal carcinomatosis. Taylor & Francis 2022-07-13 /pmc/articles/PMC9291657/ /pubmed/35859732 http://dx.doi.org/10.1080/2162402X.2022.2098657 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Brief Report Bella, Ángela Arrizabalaga, Leire Di Trani, Claudia Augusta Cirella, Assunta Fernandez-Sendin, Myriam Gomar, Celia Russo-Cabrera, Joan Salvador Rodríguez, Inmaculada González-Gomariz, José Alvarez, Maite Teijeira, Álvaro Medina-Echeverz, José Hinterberger, Maria Hochrein, Hubertus Melero, Ignacio Berraondo, Pedro Aranda, Fernando Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis |
title | Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis |
title_full | Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis |
title_fullStr | Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis |
title_full_unstemmed | Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis |
title_short | Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis |
title_sort | synergistic antitumor response with recombinant modified virus ankara armed with cd40l and cd137l against peritoneal carcinomatosis |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291657/ https://www.ncbi.nlm.nih.gov/pubmed/35859732 http://dx.doi.org/10.1080/2162402X.2022.2098657 |
work_keys_str_mv | AT bellaangela synergisticantitumorresponsewithrecombinantmodifiedvirusankaraarmedwithcd40landcd137lagainstperitonealcarcinomatosis AT arrizabalagaleire synergisticantitumorresponsewithrecombinantmodifiedvirusankaraarmedwithcd40landcd137lagainstperitonealcarcinomatosis AT ditraniclaudiaaugusta synergisticantitumorresponsewithrecombinantmodifiedvirusankaraarmedwithcd40landcd137lagainstperitonealcarcinomatosis AT cirellaassunta synergisticantitumorresponsewithrecombinantmodifiedvirusankaraarmedwithcd40landcd137lagainstperitonealcarcinomatosis AT fernandezsendinmyriam synergisticantitumorresponsewithrecombinantmodifiedvirusankaraarmedwithcd40landcd137lagainstperitonealcarcinomatosis AT gomarcelia synergisticantitumorresponsewithrecombinantmodifiedvirusankaraarmedwithcd40landcd137lagainstperitonealcarcinomatosis AT russocabrerajoansalvador synergisticantitumorresponsewithrecombinantmodifiedvirusankaraarmedwithcd40landcd137lagainstperitonealcarcinomatosis AT rodriguezinmaculada synergisticantitumorresponsewithrecombinantmodifiedvirusankaraarmedwithcd40landcd137lagainstperitonealcarcinomatosis AT gonzalezgomarizjose synergisticantitumorresponsewithrecombinantmodifiedvirusankaraarmedwithcd40landcd137lagainstperitonealcarcinomatosis AT alvarezmaite synergisticantitumorresponsewithrecombinantmodifiedvirusankaraarmedwithcd40landcd137lagainstperitonealcarcinomatosis AT teijeiraalvaro synergisticantitumorresponsewithrecombinantmodifiedvirusankaraarmedwithcd40landcd137lagainstperitonealcarcinomatosis AT medinaecheverzjose synergisticantitumorresponsewithrecombinantmodifiedvirusankaraarmedwithcd40landcd137lagainstperitonealcarcinomatosis AT hinterbergermaria synergisticantitumorresponsewithrecombinantmodifiedvirusankaraarmedwithcd40landcd137lagainstperitonealcarcinomatosis AT hochreinhubertus synergisticantitumorresponsewithrecombinantmodifiedvirusankaraarmedwithcd40landcd137lagainstperitonealcarcinomatosis AT meleroignacio synergisticantitumorresponsewithrecombinantmodifiedvirusankaraarmedwithcd40landcd137lagainstperitonealcarcinomatosis AT berraondopedro synergisticantitumorresponsewithrecombinantmodifiedvirusankaraarmedwithcd40landcd137lagainstperitonealcarcinomatosis AT arandafernando synergisticantitumorresponsewithrecombinantmodifiedvirusankaraarmedwithcd40landcd137lagainstperitonealcarcinomatosis |